Morgan Gallazzini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Morgan Gallazzini has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Clément Nguyen
INSERM UMR-U1151, CNRS UMR-8253, Institut Necker Enfants Malades, Université Paris Cité, Paris, France
4 shared publications- Fabiola Terzi
Université Paris Cité, INSERM UMR-U1151, CNRS UMR-8253, Institut Necker Enfants Malades, Paris, France
4 shared publications Fabiola Terzi
Mechanisms and Therapeutic Strategies of Chronic Kidney Disease, INSERM U1151-CNRS UMR 8253, Université de Paris, Institut Necker Enfants Malades, Département « Croissance et Signalisation », Hôpital Necker Enfants Malades
3 shared publicationsAniela Zablocki
Mechanisms and Therapeutic Strategies of Chronic Kidney Disease, INSERM U1151-CNRS UMR 8253, Université de Paris, Institut Necker Enfants Malades, Département « Croissance et Signalisation », Hôpital Necker Enfants Malades
2 shared publicationsLucie Yammine
Mechanisms and Therapeutic Strategies of Chronic Kidney Disease, INSERM U1151-CNRS UMR 8253, Université de Paris, Institut Necker Enfants Malades, Département « Croissance et Signalisation », Hôpital Necker Enfants Malades
2 shared publications- Nicolas Pallet
Department of Clinical Chemistry, Assistance Publique Hôpitaux de Paris, Georges Pompidou European Hospital, Paris, France
2 shared publications
Latest Publications
- 19 December 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (6) , 1174-1190
Clustered Mitochondrial Homolog Inhibition by Lipocalin-2 Orchestrates Mitochondrial Disruption and Contributes to Kidney Disease
Key Points: Lipocalin-2 inhibited clustered mitochondrial homolog (CLUH) activity and caused mitochondrial dysfunction. Loss of CLUH in kidneys triggered metabolic reprogramming and impaired mitochondrial structure. CLUH expression decreased with kidney injury and correlated with kidney function decline in patients. Background: Lipocalin-2 (LCN2) is a secreted protein involved in transporting hydrophobic molecules, regulating antibacterial responses and iron homeostasis. LCN2 expression increases after kidney damage and participates in CKD onset. We previously identified LCN2 as a regulator of mitochondrial dysfunction in renal tubular cells. This study aims to better understand LCN2's role in mitochondrial dysfunction and kidney pathology. Methods: LCN2 interactome was studied using mass spectrometry. The impact of LCN2 on clustered mitochondrial homolog (CLUH) activity was explored by immunofluorescence, Western blot, quantitative PCR, and RNA-immunoprecipitation. The role of CLUH on mitochondrial function in kidney was evaluated by RNAseq, metabolomics, electron microscopy, and immunochemistry using transgenic mice. Results: We characterized LCN2 interactome and identified CLUH in a multiprotein complex with LCN2. CLUH regulates mitochondrial homeostasis by binding mRNAs of nuclear-encoded mitochondrial proteins and promoting their translation. We demonstrated that LCN2 inhibited CLUH activity, leading to perinuclear mitochondrial clustering. We showed that CLUH was expressed in renal tubular cells and that its expression and activity decreased, while LCN2 expression increased after kidney injury leading to CKD. In human CKD patients, CLUH expression was inversely correlated with kidney lesions and kidney failure. CLUH genetic deletion in kidney nephron induced mitochondrial dysfunction and a subsequent interstitial fibrosis and kidney loss of function. Conclusions: This study shows that LCN2 forms a complex with CLUH and inhibits its activity, leading to perinuclear mitochondrial clustering. CLUH loss of function in renal tubular cells is associated with mitochondrial dysfunction and fibrosis, and in humans, CLUH expression inversely correlates with kidney lesions and loss of function.
- 19 December 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (6) , 1174-1190
Clustered Mitochondrial Homolog Inhibition by Lipocalin-2 Orchestrates Mitochondrial Disruption and Contributes to Kidney Disease
Key Points: Lipocalin-2 inhibited clustered mitochondrial homolog (CLUH) activity and caused mitochondrial dysfunction. Loss of CLUH in kidneys triggered metabolic reprogramming and impaired mitochondrial structure. CLUH expression decreased with kidney injury and correlated with kidney function decline in patients. Background: Lipocalin-2 (LCN2) is a secreted protein involved in transporting hydrophobic molecules, regulating antibacterial responses and iron homeostasis. LCN2 expression increases after kidney damage and participates in CKD onset. We previously identified LCN2 as a regulator of mitochondrial dysfunction in renal tubular cells. This study aims to better understand LCN2's role in mitochondrial dysfunction and kidney pathology. Methods: LCN2 interactome was studied using mass spectrometry. The impact of LCN2 on clustered mitochondrial homolog (CLUH) activity was explored by immunofluorescence, Western blot, quantitative PCR, and RNA-immunoprecipitation. The role of CLUH on mitochondrial function in kidney was evaluated by RNAseq, metabolomics, electron microscopy, and immunochemistry using transgenic mice. Results: We characterized LCN2 interactome and identified CLUH in a multiprotein complex with LCN2. CLUH regulates mitochondrial homeostasis by binding mRNAs of nuclear-encoded mitochondrial proteins and promoting their translation. We demonstrated that LCN2 inhibited CLUH activity, leading to perinuclear mitochondrial clustering. We showed that CLUH was expressed in renal tubular cells and that its expression and activity decreased, while LCN2 expression increased after kidney injury leading to CKD. In human CKD patients, CLUH expression was inversely correlated with kidney lesions and kidney failure. CLUH genetic deletion in kidney nephron induced mitochondrial dysfunction and a subsequent interstitial fibrosis and kidney loss of function. Conclusions: This study shows that LCN2 forms a complex with CLUH and inhibits its activity, leading to perinuclear mitochondrial clustering. CLUH loss of function in renal tubular cells is associated with mitochondrial dysfunction and fibrosis, and in humans, CLUH expression inversely correlates with kidney lesions and loss of function.
- Open Access
Lcn2 protects from cisplatin induced AKI by regulating DNA damage response via EGFR activation
SUMMARY: Background: Lipocalin 2 (Lcn2), a small-secreted protein, is an established sensitive biomarker of kidney injury. In Cisplatin (CDDP) induced acute kidney injury (AKI), Lcn2 expression is swiftly and strongly increased in suffering renal medullary tubules. While recent reports correlates Lcn2 expression in cancer cells with CDDP resistance, the role of Lcn2 in kidney tubule damaged by CDDP remains unknown. Methods: To better understand the role of Lcn2 in CDDP-induced AKI, experiments on Lcn2 +/+ or Lcn2 −/− mice as well as immortalized kidney cells knock-down (KD) for Lcn2 were conducted. Kidney function and injury were assessed using standard techniques. Cellular and molecular mechanisms were studied in WT and Lcn2 KD cells in combination with pathways inhibitors in order to gain insight Lcn2 driven mechanisms. Results: In animal injected with CDDP, Lcn2 was upregulated mostly in kidney inner medulla collecting duct while it was reabsorbed in the proximal tubules. Lcn2 −/− in mice significantly decreased kidney function compare to WT mice, while it increased parenchymal damage due to increased cell death and cast formation. Interestingly, while little to no damage were present in the medulla of CDDP injected WT animal, a clear increase of medulla tubular lesions was observed in Lcn2 −/− mice. Using Inner Medullary Collecting Duct cells (mIMDC-3), we showed that Lcn2 KD induces a p53-dependent apoptosis upon Cisplatin exposure while no effect on necrosis was observed. Finally, we demonstrated that Lcn2 drives CDDP resistance to apoptosis through the activation of the pro-survival EGFR pathway. Conclusions: We established that Lcn2 is a renoprotective protein in CDDP-induced AKI via the activation of EGFR pathway. This new mechanism might represent a new approach for the treatment of AKI.
Open AccessLcn2 protects from cisplatin induced AKI by regulating DNA damage response via EGFR activation
SUMMARY: Background: Lipocalin 2 (Lcn2), a small-secreted protein, is an established sensitive biomarker of kidney injury. In Cisplatin (CDDP) induced acute kidney injury (AKI), Lcn2 expression is swiftly and strongly increased in suffering renal medullary tubules. While recent reports correlates Lcn2 expression in cancer cells with CDDP resistance, the role of Lcn2 in kidney tubule damaged by CDDP remains unknown. Methods: To better understand the role of Lcn2 in CDDP-induced AKI, experiments on Lcn2 +/+ or Lcn2 −/− mice as well as immortalized kidney cells knock-down (KD) for Lcn2 were conducted. Kidney function and injury were assessed using standard techniques. Cellular and molecular mechanisms were studied in WT and Lcn2 KD cells in combination with pathways inhibitors in order to gain insight Lcn2 driven mechanisms. Results: In animal injected with CDDP, Lcn2 was upregulated mostly in kidney inner medulla collecting duct while it was reabsorbed in the proximal tubules. Lcn2 −/− in mice significantly decreased kidney function compare to WT mice, while it increased parenchymal damage due to increased cell death and cast formation. Interestingly, while little to no damage were present in the medulla of CDDP injected WT animal, a clear increase of medulla tubular lesions was observed in Lcn2 −/− mice. Using Inner Medullary Collecting Duct cells (mIMDC-3), we showed that Lcn2 KD induces a p53-dependent apoptosis upon Cisplatin exposure while no effect on necrosis was observed. Finally, we demonstrated that Lcn2 drives CDDP resistance to apoptosis through the activation of the pro-survival EGFR pathway. Conclusions: We established that Lcn2 is a renoprotective protein in CDDP-induced AKI via the activation of EGFR pathway. This new mechanism might represent a new approach for the treatment of AKI.
- Open Access
- 24 August 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (9) , 113032
Lipocalin-2 induces mitochondrial dysfunction in renal tubular cells via mTOR pathway activation
- 24 August 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (9) , 113032
Open AccessLipocalin-2 induces mitochondrial dysfunction in renal tubular cells via mTOR pathway activation
- Open Access
- 7 May 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (9)
Signaling pathways predisposing to chronic kidney disease progression
The loss of functional nephrons after kidney injury triggers the compensatory growth of the remaining ones to allow functional adaptation. However, in some cases, these compensatory events activate signaling pathways that lead to pathological alterations and chronic kidney disease. Little is known about the identity of these pathways and how they lead to the development of renal lesions. Here, we combined mouse strains that differently react to nephron reduction with molecular and temporal genome-wide transcriptome studies to elucidate the molecular mechanisms involved in these events. We demonstrated that nephron reduction led to 2 waves of cell proliferation: the first one occurred during the compensatory growth regardless of the genetic background, whereas the second one occurred, after a quiescent phase, exclusively in the sensitive strain and accompanied the development of renal lesions. Similarly, clustering by coinertia analysis revealed the existence of 2 waves of gene expression. Interestingly, we identified type I interferon (IFN) response as an early (first-wave) and specific signature of the sensitive (FVB/N) mice. Activation of type I IFN response was associated with G 1 /S cell cycle arrest, which correlated with p21 nuclear translocation. Remarkably, the transient induction of type I IFN response by poly(I:C) injections during the compensatory growth resulted in renal lesions in otherwise-resistant C57BL6 mice. Collectively, these results suggest that the early molecular and cellular events occurring after nephron reduction determine the risk of developing late renal lesions and point to type I IFN response as a crucial event of the deterioration process.
- 7 May 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (9)
Open AccessSignaling pathways predisposing to chronic kidney disease progression
The loss of functional nephrons after kidney injury triggers the compensatory growth of the remaining ones to allow functional adaptation. However, in some cases, these compensatory events activate signaling pathways that lead to pathological alterations and chronic kidney disease. Little is known about the identity of these pathways and how they lead to the development of renal lesions. Here, we combined mouse strains that differently react to nephron reduction with molecular and temporal genome-wide transcriptome studies to elucidate the molecular mechanisms involved in these events. We demonstrated that nephron reduction led to 2 waves of cell proliferation: the first one occurred during the compensatory growth regardless of the genetic background, whereas the second one occurred, after a quiescent phase, exclusively in the sensitive strain and accompanied the development of renal lesions. Similarly, clustering by coinertia analysis revealed the existence of 2 waves of gene expression. Interestingly, we identified type I interferon (IFN) response as an early (first-wave) and specific signature of the sensitive (FVB/N) mice. Activation of type I IFN response was associated with G 1 /S cell cycle arrest, which correlated with p21 nuclear translocation. Remarkably, the transient induction of type I IFN response by poly(I:C) injections during the compensatory growth resulted in renal lesions in otherwise-resistant C57BL6 mice. Collectively, these results suggest that the early molecular and cellular events occurring after nephron reduction determine the risk of developing late renal lesions and point to type I IFN response as a crucial event of the deterioration process.
- Open Access
- 1 November 2019
- Published by Elsevier in Cell Reports
- Vol. 29 (7) , 2067-2077.e6
Lipocalin-2 Regulates Epidermal Growth Factor Receptor Intracellular Trafficking
- 1 November 2019
- Published by Elsevier in Cell Reports
- Vol. 29 (7) , 2067-2077.e6
Open AccessLipocalin-2 Regulates Epidermal Growth Factor Receptor Intracellular Trafficking
- 10 July 2018
- Published by Wiley in Biology of the Cell
- Vol. 110 (9) , 205-216
Endoplasmic reticulum stress and kidney dysfunction
Chronic kidney disease (CKD) affects millions of persons worldwide and constitutes a major public health problem. Therefore, understanding the molecular basis of CKD is a key challenge for the development of preventive and therapeutic strategies. A major contributor to chronic histological damage associated with CKD is acute kidney injury (AKI). At the cellular level, kidney injuries are associated with microenvironmental alterations, forcing cells to activate adaptive biological processes that eliminate the stressor and generate alarm signals. These signalling pathways actively participate in tissue remodelling by promoting inflammation and fibrogenesis, ultimately leading to CKD. Many stresses that are encountered upon kidney injury are prone to trigger endoplasmic reticulum (ER) stress. In the kidney, ER stress both participates in acute and chronic histological damages, but also promotes cellular adaptation and nephroprotection. In this review, we will discuss the implication of ER stress in the pathophysiology of AKI and CKD progression, and we will give a critical analysis of the current experimental and clinical evidence that support ER stress as a mediator of kidney damage.
- 10 July 2018
- Published by Wiley in Biology of the Cell
- Vol. 110 (9) , 205-216
Endoplasmic reticulum stress and kidney dysfunction
Chronic kidney disease (CKD) affects millions of persons worldwide and constitutes a major public health problem. Therefore, understanding the molecular basis of CKD is a key challenge for the development of preventive and therapeutic strategies. A major contributor to chronic histological damage associated with CKD is acute kidney injury (AKI). At the cellular level, kidney injuries are associated with microenvironmental alterations, forcing cells to activate adaptive biological processes that eliminate the stressor and generate alarm signals. These signalling pathways actively participate in tissue remodelling by promoting inflammation and fibrogenesis, ultimately leading to CKD. Many stresses that are encountered upon kidney injury are prone to trigger endoplasmic reticulum (ER) stress. In the kidney, ER stress both participates in acute and chronic histological damages, but also promotes cellular adaptation and nephroprotection. In this review, we will discuss the implication of ER stress in the pathophysiology of AKI and CKD progression, and we will give a critical analysis of the current experimental and clinical evidence that support ER stress as a mediator of kidney damage.
- 1 April 2016
- Published by JLE in Nephrologie & Therapeutique
- Vol. 12, S35-S38
Molecular pathways of chronic kidney disease progression
Chronic kidney disease is characterized by the progressive loss of functional nephrons. This loss means that the remaining nephrons are put under stress and are forced to adapt in order to maintain kidney function. Over the time, the strains imposed by these adaptations result in a vicious circle in which the loss of damaged nephrons results in the damage of the so far healthy nephrons. Hence, the rate of chronic kidney disease progression depends on the ability of the remaining nephrons to cope with stress. This article reviews the molecular pathways involved in the compensation and deterioration process after nephron reduction. In particular, we examine the role of mammalian target of rapamycin complex (mTORC)/serine-threonine protein kinase AKT, epidermal growth factor receptor (EGFR) and unfolded protein response pathways, as well as the pleiotropic function of Lipocalin 2. We also discuss the dual role played by some of these pathways in acute and chronic kidney disease. Finally, the relevance of these experimental finding to human chronic kidney disease is discussed.
- 1 April 2016
- Published by JLE in Nephrologie & Therapeutique
- Vol. 12, S35-S38
Molecular pathways of chronic kidney disease progression
Chronic kidney disease is characterized by the progressive loss of functional nephrons. This loss means that the remaining nephrons are put under stress and are forced to adapt in order to maintain kidney function. Over the time, the strains imposed by these adaptations result in a vicious circle in which the loss of damaged nephrons results in the damage of the so far healthy nephrons. Hence, the rate of chronic kidney disease progression depends on the ability of the remaining nephrons to cope with stress. This article reviews the molecular pathways involved in the compensation and deterioration process after nephron reduction. In particular, we examine the role of mammalian target of rapamycin complex (mTORC)/serine-threonine protein kinase AKT, epidermal growth factor receptor (EGFR) and unfolded protein response pathways, as well as the pleiotropic function of Lipocalin 2. We also discuss the dual role played by some of these pathways in acute and chronic kidney disease. Finally, the relevance of these experimental finding to human chronic kidney disease is discussed.
- 13 October 2014
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 207 (1) , 2071OIA181-2071
Regulation of YAP by mTOR and autophagy reveals a therapeutic target of Tuberous Sclerosis Complex
- 13 October 2014
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 207 (1) , 2071OIA181-2071
Regulation of YAP by mTOR and autophagy reveals a therapeutic target of Tuberous Sclerosis Complex